Trastuzumab in Breast Cancer Treatment: The Era of Biosimilars

Page: [2507 - 2516] Pages: 10

  • * (Excluding Mailing and Handling)

Abstract

Background: The discovery of trastuzumab as anti-HER2 therapy has markedly improved disease control and the survival rates of patients with HER2+ breast cancer. However, as trastuzumab is considered a complex molecule, the cost of production is usually elevated, which significantly affects health budgets and limits the treatment access for patients who live in underdeveloped countries. Recently, trastuzumab production has become more accessible and sustainable due to the patents’ expiration, allowing biosimilar versions of trastuzumab to be developed.

Objective: Our main goal was to shed more light on the uses of biosimilars in breast cancer treatment, emphasizing trastuzumab.

Method: An integrative search was carried out on the PubMed, Scielo, Web of Science, and SCOPUS databases using the terms “biosimilar,” “breast cancer,” “monoclonal antibody,” and “trastuzumab.” The time range included scientific articles published from 2015 to 2021.

Results and Discussion: The bibliographic survey showed the complexities in biological medicine manufacturing and how the monoclonal antibody’s therapy with trastuzumab improved the patients’ life expectancy, revolutionizing HER2+ breast cancer treatment. Nonetheless, despite its benefits, trastuzumab generates certain restrictions, especially from the economic perspective. Trastuzumab biosimilars have high selectivity and rarely cause adverse effects compared to conventional chemotherapy.

Conclusion: This study shows that trastuzumab biosimilars improve patients’ accessibility to breast cancer treatment through a safe and effective therapy compared to the drug reference.

Keywords: Biological medicines, biosimilars, anti-HER2, trastuzumab biosimilar, immunobiological therapy, breast cancer.

Graphical Abstract

[1]
Barbier, L.; Declerck, P.; Simoens, S.; Neven, P.; Vulto, A.G.; Huys, I. The arrival of biosimilar monoclonal antibodies in oncology: clini-cal studies for trastuzumab biosimilars. Br. J. Cancer, 2019, 121(3), 199-210.
[http://dx.doi.org/10.1038/s41416-019-0480-z] [PMID: 31257362]
[2]
Zelenetz, A.D. The era of therapeutic biosimilars has arrived: What you need to know. J. Natl. Compr. Canc. Netw. 2019, 17(11.5), 1424-1426.
[http://dx.doi.org/10.6004/jnccn.2019.5036] [PMID: 31766021]
[3]
Verrill, M.; Declerck, P.; Loibl, S.; Lee, J.; Cortes, J. The rise of oncology biosimilars: from process to promise. Future Oncol., 2019, 15(28), 3255-3265.
[http://dx.doi.org/10.2217/fon-2019-0145] [PMID: 31441323]
[4]
Waller, C.F. Friganovi A. Biosimilars in oncology: key role of nurses in patient education. Future Oncol., 2020, 16(25), 1931-1939.
[http://dx.doi.org/10.2217/fon-2020-0486] [PMID: 32618476]
[5]
Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin., 2021, 71(1), 7-33.
[http://dx.doi.org/10.3322/caac.21654] [PMID: 33433946]
[6]
INCA. A situação do câncer de mama no Brasil: Síntese de dados dos Sistemas de Iformação. Inst Nac Câncer José Alencar Gomes da Silva - INCA Ministério da Saúde - Rio Janeiro, 85 2019,
[7]
INCA. Estimativas 2020: Incidência do Câncer no Brasil. Inst Nac Câncer José Alencar Gomes da Silva Ministério da Saúde - Rio Janeiro, 2019.
[8]
Cristina, I.; Ohl, B.; Isabel, R.; Ohl, B.; Regina, S.; Chavaglia, R. Ações publicas para o controle de cancer no Brasil. Rev. Bras. Enferm., 2016, 69(4), 793-803.
[http://dx.doi.org/10.1590/0034-7167.2016690424i] [PMID: 27508487]
[9]
Debiasi, M.; Reinert, T.; Kaliks, R.; Amorim, G.; Caleffi, M.; Sampaio, C.; Fernandes, G.D.S.; Barrios, C.H. Estimation of premature deaths from lack of access to anti-HER2 therapy for advanced breast cancer in the Brazilian public health system. J. Glob. Oncol., 2016, 3(3), 201-207.
[http://dx.doi.org/10.1200/JGO.2016.005678] [PMID: 28717761]
[10]
Kondov, B.; Milenkovikj, Z.; Kondov, G.; Petrushevska, G.; Basheska, N.; Bogdanovska-Todorovska, M.; Tolevska, N.; Ivkovski, L. Presentation of the molecular subtypes of breast cancer detected by immunohistochemistry in surgically treated patients. Open Access Maced. J. Med. Sci., 2018, 6(6), 961-967.
[http://dx.doi.org/10.3889/oamjms.2018.231] [PMID: 29983785]
[11]
Peckys, D.B.; Hirsch, D.; Gaiser, T.; de Jonge, N. Visualisation of HER2 homodimers in single cells from HER2 overexpressing primary formalin fixed paraffin embedded tumour tissue. Mol. Med., 2019, 25(1), 42.
[http://dx.doi.org/10.1186/s10020-019-0108-z] [PMID: 31455202]
[12]
Zhang, X.; Chen, J.; Weng, Z.; Li, Q.; Zhao, L.; Yu, N.; Deng, L.; Xu, W.; Yang, Y.; Zhu, Z.; Huang, H. A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action. Mol. Immunol., 2020, 119, 48-58.
[http://dx.doi.org/10.1016/j.molimm.2020.01.009] [PMID: 31978707]
[13]
Tong, C.W.S.; Wu, M.; Cho, W.C.S.; To, K.K.W. Recent advances in the treatment of breast cancer. Front. Oncol., 2018, 8, 227.
[PMID: 29963498]
[14]
Pohlmann, P.R.; Mayer, I.A.; Mernaugh, R. Resistance to trastuzumab in breast cancer. Clin. Cancer Res., 2009, 15(24), 7479-7491.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-0636] [PMID: 20008848]
[15]
Redman, J.M.; Hill, E.M.; AlDeghaither, D.; Weiner, L.M. Mechanisms of action of therapeutic antibodies for cancer. Mol. Immunol., 2015, 67(2 Pt A), 28-45.
[PMID: 25911943]
[16]
Nieto, C.; Vega, M.A.; Del Valle, E.M.M. Trastuzumab: More than a guide in her2-positive cancer nanomedicine. Nanomaterials (Basel), 2020, 10(9), 1674.
[PMID: 32859026]
[17]
Stewart, P.; Blanchette, P.; Shah, P.S.; Ye, X.Y.; Boldt, R.G.; Fernandes, R.; Vandenberg, T.; Raphael, J. Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis. Breast, 2020, 54, 203-210.
[http://dx.doi.org/10.1016/j.breast.2020.10.003] [PMID: 33130486]
[18]
Trapani, D.; Curigliano, G. How can biosimilars change the trajectory of breast cancer therapy? Expert Rev. Anticancer Ther., 2020, 20(5), 325-328.
[http://dx.doi.org/10.1080/14737140.2020.1757438] [PMID: 32298188]
[19]
Yakes, F.M.; Chinratanalab, W.; Ritter, C.A.; King, W.; Seelig, S.; Arteaga, C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res., 2002, 62(14), 4132-4141.
[PMID: 12124352]
[20]
Maadi, H.; Soheilifar, M.H.; Choi, W.S.; Moshtaghian, A.; Wang, Z. Trastuzumab mechanism of action; 20 years of research to unravel a dilemma. Cancers (Basel), 2021, 13(14), 1-17.
[http://dx.doi.org/10.3390/cancers13143540] [PMID: 34298754]
[21]
Bruno, R.; Washington, C.B.; Lu, J.F.; Lieberman, G.; Banken, L.; Klein, P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother. Pharmacol., 2005, 56(4), 361-369.
[http://dx.doi.org/10.1007/s00280-005-1026-z] [PMID: 15868146]
[22]
Levêque, D.; Gigou, L.; Bergerat, J.P. Clinical pharmacology of trastuzumab. Curr. Clin. Pharmacol., 2008, 3(1), 51-55.
[http://dx.doi.org/10.2174/157488408783329931] [PMID: 18690878]
[23]
ANVISA. Herceptin® sc - Bula atualizada 04/01/2021; Prod Roche Químicos e Farm SA, 2021, pp. 1-122.
[24]
Blackwell, K.; Gligorov, J.; Jacobs, I.; Twelves, C. The global need for a trastuzumab biosimilar for patients with HER2-positive breast cancer. Clin. Breast Cancer, 2018, 18(2), 95-113.
[http://dx.doi.org/10.1016/j.clbc.2018.01.006] [PMID: 29525430]
[25]
Maximiano, S.; Magalhães, P.; Guerreiro, M.P.; Morgado, M. Trastuzumab in the treatment of breast cancer. BioDrugs, 2016, 30(2), 75-86.
[http://dx.doi.org/10.1007/s40259-016-0162-9] [PMID: 26892619]
[26]
Cuellar, S.; McBride, A.; Medina, P. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice. Am. J. Heal. Pharm., 2019, 76(21), 1725-1738.
[http://dx.doi.org/10.1093/ajhp/zxz190] [PMID: 31612935]
[27]
Kabir, E.R.; Moreino, S.S.; Sharif Siam, M.K. The breakthrough of biosimilars: A twist in the narrative of biological therapy. Biomolecules, 2019, 9(9), E410.
[http://dx.doi.org/10.3390/biom9090410] [PMID: 31450637]
[28]
Kirchhoff, C.F.; Wang, X.Z.M.; Conlon, H.D.; Anderson, S.; Ryan, A.M.; Bose, A. Biosimilars: Key regulatory considerations and similar-ity assessment tools. Biotechnol. Bioeng., 2017, 114(2), 2696-2705.
[PMID: 28842986]
[29]
Pimentel, F.F. Biossimilares em oncologia. In: Santos M, Corrêa TS, Faria LD. Diretrizes Oncológicas 2. São Paulo: Doctor Press Ed. Científica,, 2019. cap. 38. p.607-18.
[30]
EMA. Biosimilar medicines: Overview | European Medicines Agency 2021. Available from: 2021.https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview
[31]
Nixon, N.A.; Hannouf, M.B.; Verma, S. The evolution of biosimilars in oncology, with a focus on trastuzumab. Curr. Oncol., 2018, 25(Suppl. 1), S171-S179.
[http://dx.doi.org/10.3747/co.25.3942] [PMID: 29910660]
[32]
Lyman, G.H.; Zon, R.; Harvey, R.D.; Schilsky, R.L. Rationale, opportunities, and reality of biosimilar medications. N. Engl. J. Med., 2018, 378(21), 2036-2044.
[http://dx.doi.org/10.1056/NEJMhle1800125] [PMID: 29791832]
[33]
Beck, A.; Debaene, F.; Diemer, H.; Wagner-Rousset, E.; Colas, O.; Van Dorsselaer, A.; Cianférani, S. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies. J. Mass Spectrom., 2015, 50(2), 285-297.
[http://dx.doi.org/10.1002/jms.3554] [PMID: 25800010]
[34]
D’Atri, V.; Fekete, S.; Beck, A.; Lauber, M.; Guillarme, D. Hydrophilic interaction chromatography hyphenated with mass spectrometry: A powerful analytical tool for the comparison of originator and biosimilar therapeutic monoclonal antibodies at the middle-up level of analy-sis. Anal. Chem., 2017, 89(3), 2086-2092.
[http://dx.doi.org/10.1021/acs.analchem.6b04726] [PMID: 28208257]
[35]
Joshi, S.; Rathore, A.S. Assessment of structural and functional comparability of biosimilar products: trastuzumab as a case study. BioDrugs, 2020, 34(2), 209-223.
[http://dx.doi.org/10.1007/s40259-020-00404-3] [PMID: 31975160]
[36]
Joshi, S.; Kumari, S.; Rathore, A.S. Identification and characterization of carbonylation sites in trastuzumab biosimilars. Int. J. Biol. Macromol., 2021, 169, 95-102.
[http://dx.doi.org/10.1016/j.ijbiomac.2020.12.095] [PMID: 33338527]
[37]
Janjigian, Y.Y.; Bissig, M.; Curigliano, G.; Coppola, J.; Latymer, M. Talking to patients about biosimilars. In: Future Oncol;, 2018. 14, pp. (23)2403-2414.
[PMID: 29856243]
[38]
Fernandes, G.S.; Sternberg, C.; Lopes, G.; Chammas, R.; Gifoni, M.A.C.; Gil, R.A.; Araujo, D.V. The use of biosimilar medicines in on-cology - position statement of the Brazilian society of clinical oncology (SBOC). Braz. J. Med. Biol. Res., 2018, 51(3), e7214.
[http://dx.doi.org/10.1590/1414-431x20177214] [PMID: 29340530]
[39]
Declerck, P.; Danesi, R.; Petersel, D.; Jacobs, I. The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs, 2017, 77(6), 671-677.
[PMID: 28258517]
[40]
Clark, T.; Jo, S.J.; Phillips, A. Sample size for biosimilar trials: In defense of synthesis. Ther. Innov. Regul. Sci., 2018, 52(3), 300-305.
[PMID: 29714537]
[41]
Buske, C.; Ogura, M.; Kwon, H.C.; Yoon, S.W. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements. Future Oncol., 2017, 13(15s), 5-16.
[http://dx.doi.org/10.2217/fon-2017-0153] [PMID: 28482702]
[42]
Lüftner, D.; Lyman, G.H.; Gonçalves, J.; Pivot, X.; Seo, M. Biologic drug quality assurance to optimize HER2 + breast cancer treatment: Insights from development of the trastuzumab biosimilar SB3. Target. Oncol., 2020, 15(4), 467-475.
[PMID: 32748046]
[43]
Rugo, H.S.; Barve, A.; Waller, C.F.; Hernandez-Bronchud, M.; Herson, J.; Yuan, J.; Sharma, R.; Baczkowski, M.; Kothekar, M.; Loga-nathan, S.; Manikhas, A.; Bondarenko, I.; Mukhametshina, G.; Nemsadze, G.; Parra, J.D.; Abesamis-Tiambeng, M.L.; Baramidze, K.; Akewanlop, C.; Vynnychenko, I.; Sriuranpong, V.; Mamillapalli, G.; Ray, S.; Yanez Ruiz, E.P.; Pennella, E. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A randomized clinical trial. JAMA -. JAMA, 2017, 317(1), 37-47.
[http://dx.doi.org/10.1001/jama.2016.18305] [PMID: 27918780]
[44]
Cohen, H.P.; Blauvelt, A.; Rifkin, R.M.; Danese, S.; Gokhale, S.B.; Woollett, G. Switching reference medicines to biosimilars: A systematic literature review of clinical outcomes. Drugs, 2018, 78(4), 463-478.
[PMID: 29500555]
[45]
Hübel, K.; Kron, F.; Lux, M.P. Biosimilars in oncology: Effects on economy and therapeutic innovations. Eur. J. Cancer, 2020, 139, 10-19.
[http://dx.doi.org/10.1016/j.ejca.2020.07.037] [PMID: 32950935]
[46]
Kaida-Yip, F.; Deshpande, K.; Saran, T.; Vyas, D. Biosimilars: Review of current applications, obstacles, and their future in medicine. World J. Clin. Cases, 2018, 6(8), 161-166.
[http://dx.doi.org/10.12998/wjcc.v6.i8.161] [PMID: 30148143]
[47]
Pimenta, M.V.; Monteiro, G. The production of biopharmaceuticals in Brazil: Current issues. Braz. J. Pharm. Sci., 2019, 55, 17823.
[http://dx.doi.org/10.1590/s2175-97902019000217823]
[48]
Vulto, A.G.; Jaquez, O.A. The process defines the product: what really matters in biosimilar design and production? Rheumatology (Oxford),, 2017. 56(Suppl_4), iv14-iv29.
[http://dx.doi.org/10.1093/rheumatology/kex278] [PMID: 28903544]
[49]
López-Morales, C.A.; Miranda-Hernández, M.P.; Juárez-Bayardo, L.C.; Ramírez-Ibáñez, N.D.; Romero-Díaz, A.J.; Piña-Lara, N. Physico-chemical and biological characterization of a biosimilar trastuzumab. BioMed Res. Int., 2015, 2015, 427235.
[http://dx.doi.org/10.1155/2015/427235] [PMID: 26075238]
[50]
Dranitsaris, G.; Amir, E.; Dorward, K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs, 2011, 71(12), 1527-1536.
[http://dx.doi.org/10.2165/11593730-000000000-00000] [PMID: 21861538]
[51]
Mellstedt, H.; Niederwieser, D.; Ludwig, H. The challenge of biosimilars. Ann. Oncol., 2008, 19(3), 411-419.
[http://dx.doi.org/10.1093/annonc/mdm345] [PMID: 17872902]
[52]
Andrews, L.; Ralston, S.; Blomme, E.; Barnhart, K. A snapshot of biologic drug development: Challenges and opportunities. Hum. Exp. Toxicol., 2015, 34(12), 1279-1285.
[http://dx.doi.org/10.1177/0960327115603594] [PMID: 26614816]
[53]
Kantardjieff, A.; Zhou, W. Mammalian cell cultures for biologics manufacturing. Adv. Biochem. Eng. Biotechnol., 2014, 139, 1-9.
[PMID: 24258145]
[54]
Woodcock, J.; Griffin, J.; Behrman, R.; Cherney, B.; Crescenzi, T.; Fraser, B.; Hixon, D.; Joneckis, C.; Kozlowski, S.; Rosenberg, A.; Schrager, L.; Shacter, E.; Temple, R.; Webber, K.; Winkle, H. The FDA’s assessment of follow-on protein products: a historical perspec-tive. Nat. Rev. Drug Discov., 2007, 6(6), 437-442.
[http://dx.doi.org/10.1038/nrd2307] [PMID: 17633790]
[55]
Zhu, M.M.; Mollet, M.; Hubert, R.S.; Kyung, Y.S.; Zhang, G.G. Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification. In: Handbook of Industrial Chemistry and Biotechnology; Kent, J.A.; Bommaraju, T.V.; Barnicki, S.D., Eds.; Springer: Cham, 2017; pp. 1639-1669.
[http://dx.doi.org/10.1007/978-3-319-52287-6_29]
[56]
Brezinsky, S.C.G.; Chiang, G.G.; Szilvasi, A.; Mohan, S.; Shapiro, R.I.; MacLean, A.; Sisk, W.; Thill, G. A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity. J. Immunol. Methods, 2003, 277(1-2), 141-155.
[http://dx.doi.org/10.1016/S0022-1759(03)00108-X] [PMID: 12799047]
[57]
Jozala, A.F.; Geraldes, D.C.; Tundisi, L.L.; Feitosa, V. de A.; Breyer, C.A.; Cardoso, S.L. Biopharmaceuticals from microorganisms: from production to purification. Braz. J. Microbiol., 2016, 47(Suppl. 1), 51-63.
[PMID: 27838289]
[58]
Fishman, J.B.; Berg, E.A. Antibody purification and storage. Cold Spring Harb. Protoc., 2019, 2019(5), 331-344.
[PMID: 31043563]
[59]
Ramos-de-la-Peña, A.M.; González-Valdez, J.; Aguilar, O. Protein A chromatography: Challenges and progress in the purification of mon-oclonal antibodies. J. Sep. Sci., 2019, 42(9), 1816-1827.
[PMID: 30811843]
[60]
Stein, A.; Kiesewetter, A. Cation exchange chromatography in antibody purification: pH screening for optimised binding and HCP remov-al. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 848(1), 151-158.
[http://dx.doi.org/10.1016/j.jchromb.2006.10.010] [PMID: 17113367]
[61]
Cummings, L.J.; Frost, R.G.; Snyder, M.A. Monoclonal antibody purification by ceramic hydroxyapatite chromatography. Methods Mol. Biol., 2014, 1131, 241-251.
[http://dx.doi.org/10.1007/978-1-62703-992-5_15] [PMID: 24515470]
[62]
Shibui, T.; Bando, K.; Misawa, S. High-level secretory expression, purification, and characterization of an anti-human Her II monoclonal antibody, trastuzumab, in the methylotrophic yeast Pichia pastoris. Adv. Biosci. Biotechnol., 2013, 04(05), 640-646.
[http://dx.doi.org/10.4236/abb.2013.45084]
[63]
Liu, H.F.; Ma, J.; Winter, C.; Bayer, R. Recovery and purification process development for monoclonal antibody production; Taylor & Francis, 2010. 2, p. 2.
[64]
Gronemeyer, P.; Ditz, R.; Strube, J. Trends in upstream and downstream process development for antibody manufacturing. In: Bioengineering; MDPI AG, 2014. 1, pp. 188-212.
[65]
Makurvet, F.D. Biologics vs. small molecules: Drug costs and patient access. Med Drug Discov, 2021, 9, 100075.
[http://dx.doi.org/10.1016/j.medidd.2020.100075]
[66]
Cuellar, S. Integrating trastuzumab biosimilars and HER2-directed therapies into HER2-positive breast cancer management. Am. J. Manag. Care, 2020, 26(2)(Suppl.), S32-S40.
[PMID: 32282173]
[67]
Huang, H.Y.; Liu, C.C.; Yu, Y.; Wang, L.; Wu, D.W.; Guo, L.W. Pharmacoeconomic evaluation of cancer biosimilars worldwide: A sys-tematic review. Front. Pharmacol., 2020, 11, 572569.
[PMID: 33536905]
[68]
Paplomata, E.; Nahta, R. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer. Expert Opin. Biol. Ther., 2018, 18(3), 335-341.
[http://dx.doi.org/10.1080/14712598.2018.1430761] [PMID: 29350568]
[69]
Lechat, P. Biosimilar medicines: Regulatory issues and medico-economic impacts. Bull. Acad Natl. Med., 2020, 204(8), 877-883.
[PMID: 32836292]
[70]
Miller, E.M.; Schwartzberg, L.S. Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States. Ther. Adv. Med. Oncol., 2019, 11, 1758835919887044.
[PMID: 31798693]
[71]
Stebbing, J.; Baranau, Y.; Baryash, V.; Manikhas, A.; Moiseyenko, V.; Dzagnidze, G.; Zhavrid, E.; Boliukh, D.; Stroyakovskii, D.; Pikiel, J.; Eniu, A.; Komov, D.; Morar-Bolba, G.; Li, R.K.; Rusyn, A.; Lee, S.J.; Lee, S.Y.; Esteva, F.J. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol., 2017, 18(7), 917-928.
[http://dx.doi.org/10.1016/S1470-2045(17)30434-5] [PMID: 28592386]
[72]
Pivot, X.; Bondarenko, I.; Nowecki, Z.; Dvorkin, M.; Trishkina, E.; Ahn, J.H.; Vinnyk, Y. Im, S.A.; Sarosiek, T.; Chatterjee, S.; Wojtukiewicz, M.Z.; Moiseyenko, V.; Shparyk, Y.; Bello, M., III; Semiglazov, V.; Song, S.; Lim, J. Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. J. Clin. Oncol., 2018, 36(10), 968-974.
[http://dx.doi.org/10.1200/JCO.2017.74.0126] [PMID: 29373094]
[73]
Lammers, P.E.; Dank, M.; Masetti, R.; Abbas, R.; Hilton, F.; Coppola, J.; Jacobs, I. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. Br. J. Cancer, 2018, 119(3), 266-273.
[http://dx.doi.org/10.1038/s41416-018-0147-1] [PMID: 30002437]
[74]
von Minckwitz, G.; Procter, M.; de Azambuja, E.; Zardavas, D.; Benyunes, M.; Viale, G.; Suter, T.; Arahmani, A.; Rouchet, N.; Clark, E.; Knott, A.; Lang, I.; Levy, C.; Yardley, D.A.; Bines, J.; Gelber, R.D.; Piccart, M.; Baselga, J. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N. Engl. J. Med., 2017, 377(2), 122-131.
[http://dx.doi.org/10.1056/NEJMoa1703643] [PMID: 28581356]
[75]
Calleja-Hernández, M.Á.; Martínez-Sesmero, J.M.; Santiago-Josefat, B. Biosimilars of monoclonal antibodies in inflammatory diseases and cancer: current situation, challenges, and opportunities. Farm. Hosp., 2020, 44(3), 100-108.
[PMID: 32452309]
[76]
Declerck, P.; Bakalos, G.; Zintzaras, E.; Barton, B.; Schreitmüller, T. Monoclonal antibody biosimilars in oncology: Critical appraisal of available data on switching. Clin. Ther., 2018, 40(5), 798-809.e2.
[http://dx.doi.org/10.1016/j.clinthera.2018.03.018] [PMID: 29699853]
[77]
Farhat, F.; Torres, A.; Park, W.; de Lima Lopes, G.; Mudad, R.; Ikpeazu, C.; Abi Aad, S. The concept of biosimilars: From characterization to evolution-a narrative review. Oncologist, 2018, 23(3), 346-352.
[http://dx.doi.org/10.1634/theoncologist.2017-0126] [PMID: 29284760]
[78]
Lee, S.M.; Jung, J.H.; Suh, D.; Jung, Y.S.; Yoo, S.L.; Kim, D.W.; Kim, J.A.; Suh, D.C. Budget impact of switching to biosimilar trastuzumab (CT-P6) for the treatment of breast cancer and gastric cancer in 28 European countries. BioDrugs, 2019, 33(4), 423-436.
[http://dx.doi.org/10.1007/s40259-019-00359-0] [PMID: 31201616]
Request history8.2.27PHP Version256msRequest Duration27MBMemory UsageGET article/{article_id}/{param?}Route
  • warninglog[19:10:00] LOG.warning: Optional parameter $article_id declared before required parameter $request i...
  • warninglog[19:10:01] LOG.warning: trim(): Passing null to parameter #1 ($string) of type string is deprecated ...
  • warninglog[19:10:01] LOG.warning: Function strftime() is deprecated in /home/betabenthamscien/public_html/stor...
  • warninglog[19:10:01] LOG.warning: Function strftime() is deprecated in /home/betabenthamscien/public_html/stor...
  • Booting (90.39ms)time
  • Application (166ms)time
  • 1 x Application (64.73%)
    166ms
    1 x Booting (35.27%)
    90.39ms
    8 templates were rendered
    • articlearticle.blade.php#?blade
    • includes.journal_rightmenujournal_rightmenu.blade.php#?blade
    • includes.article_top_bannerarticle_top_banner.blade.php#?blade
    • includes.article_referencearticle_reference.blade.php#?blade
    • layouts.appapp.blade.php#?blade
    • layouts._login_access_login_access.blade.php#?blade
    • layouts._main_menu_main_menu.blade.php#?blade
    • layouts._footer_menu_footer_menu.blade.php#?blade
    uri
    GET article/{article_id}/{param?}
    middleware
    web, check_user_access
    controller
    App\Http\Controllers\ArticleController@GetArticleDetails
    namespace
    App\Http\Controllers
    where
    as
    article
    file
    app/Http/Controllers/ArticleController.php:1974-2510
    30 statements were executed, 2 of which were duplicates, 28 unique. Show only duplicated103ms
    • Connection Establishedalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 9. middleware::check_user_access:24
      • 10. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 11. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address (ip_address,visitor_agent,visitor_count, created_on,updated_on) VALUES ('59837029','',1,1736968200,1736968200) ON DUPLICATE KEY UPDATE visitor_count=visitor_count + 1, updated_on=1736968200
      1.01msalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 11. middleware::check_user_access:24
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address_detail (ip_address,visitor_url,visitor_count, created_on,updated_on) VALUES ('59837029','/article/121242',1,1736968200,1736968200)
      690μsalphaeurekaselec_live_10_06_2022UserAccessCheck.php#27
      Backtrace
      • 11. middleware::check_user_access:27
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_trail WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_corporate WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_token WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_trail WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_corporate WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_token WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_trail WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_corporate WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_token WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_trail WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_corporate WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_token WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_trail WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_corporate WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_token WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_disease_corporate WHERE to_ip >= 59837029 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 59837029) limit 1
      6.13msalphaeurekaselec_live_10_06_2022UserAccess.php#784
      Bindings
      • 0: 59837029
      • 1: 59837029
      • 2: 59837029
      • 3: 59837029
      • 4: 59837029
      • 5: 59837029
      • 6: 59837029
      • 7: 59837029
      • 8: 59837029
      • 9: 59837029
      • 10: 59837029
      • 11: 59837029
      • 12: 59837029
      • 13: 59837029
      • 14: 59837029
      • 15: 59837029
      Backtrace
      • 14. app/Models/UserAccess/UserAccess.php:784
      • 15. middleware::check_user_access:63
      • 16. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 18. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
    • SELECT at.type_name, p.copyright, p.publisher_location,m.month,y.year, a.publish_on, a.nid article_nid,a.article_id, a.pmid, a.issue_id, a.title, a.abstract,a.podcast,a.altmetric_score,a.altmetric_url,a.kudos_url, a.page_count, a.first_page, a.elocator, a.last_page, i.publication_date, a.file_name, a.file_path, a.doi, a.is_epub,a.epub_type, a.volume_id, a.is_uploaded, a.editor_choice, a.is_epub, j.image_file_name, a.article_no, a.art_type AS article_type, a.supplementary_filename,a.html_filename,a.prc_filename,a.epub_filename, a.graph_abs_lg_filename, a.graph_abs_sm_filename, a.oa_image_lg_filename, a.oa_image_sm_filename, j.journal_banner,a.animated_abstract,a.erratum_in,a.erratum_for, (CASE WHEN a.issue_id =0 THEN j.epub_price ELSE j.price END) AS sell_price, j.epub_price, j.nid AS jour_nid, j.title AS journal_title, j.issn, j.eissn,j.journal_id, j.subtitle AS jour_subtitle, v.volume_id,v.volume_name AS volume, v.year_id, i.title AS issue, i.month_id ,i.type issue_type, j.subtitle,j.formerly_title, ac.subtitle AS epub_title,a.crossmark_enabled,a.text_mining_urls,a.license_urls,a.created, a.receivedate, a.revisedate, a.acceptdate,js.js_title FROM article a LEFT JOIN article_section ac ON a.is_epub = ac.art_sec_id LEFT JOIN journal_section js ON a.js_id = js.js_id LEFT JOIN article_type at ON a.art_type = at.art_type_id LEFT JOIN issue i ON a.issue_id = i.issue_id LEFT JOIN month m ON m.id = i.month_id LEFT JOIN volume v ON v.volume_id = a.volume_id INNER JOIN year y ON y.id = v.year_id INNER JOIN journal j ON j.journal_id = a.journal_id INNER JOIN publisher p ON p.publisher_id = j.publisher_id WHERE a.article_id=121242
      950μsalphaeurekaselec_live_10_06_2022Article.php#408
      Backtrace
      • 11. app/Models/Article.php:408
      • 12. app/Http/Controllers/ArticleController.php:2515
      • 13. app/Http/Controllers/ArticleController.php:2035
      • 14. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 15. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `journal` where `journal_id` = 1 limit 1
      950μsalphaeurekaselec_live_10_06_2022Journal.php#64
      Bindings
      • 0: 1
      Backtrace
      • 14. app/Models/Journal.php:64
      • 15. app/Http/Controllers/ArticleController.php:2516
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=1) and sj.journal_id!=1 group by `j`.`nid`) as `aggregate_table`
      1.9msalphaeurekaselec_live_10_06_2022Subject.php#198
      Backtrace
      • 16. app/Models/Subject.php:198
      • 17. app/Http/Controllers/ArticleController.php:2517
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=1) and sj.journal_id!=1 group by `j`.`nid` order by `j`.`journal_id` asc limit 10 offset 0
      1.52msalphaeurekaselec_live_10_06_2022Subject.php#198
      Backtrace
      • 14. app/Models/Subject.php:198
      • 15. app/Http/Controllers/ArticleController.php:2517
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=1) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid`) as `aggregate_table`
      4.87msalphaeurekaselec_live_10_06_2022Subject.php#218
      Backtrace
      • 16. app/Models/Subject.php:218
      • 17. app/Http/Controllers/ArticleController.php:2518
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=1) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid` order by `v`.`ebook_volume_id` desc limit 10 offset 0
      3.93msalphaeurekaselec_live_10_06_2022Subject.php#218
      Backtrace
      • 14. app/Models/Subject.php:218
      • 15. app/Http/Controllers/ArticleController.php:2518
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `keywords` where `article_id` = '121242'
      350μsalphaeurekaselec_live_10_06_2022Keywords.php#85
      Bindings
      • 0: 121242
      Backtrace
      • 13. app/Models/Keywords.php:85
      • 14. app/Http/Controllers/ArticleController.php:2519
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `article_citation` where `article_id` = '121242'
      4.34msalphaeurekaselec_live_10_06_2022Article.php#1569
      Bindings
      • 0: 121242
      Backtrace
      • 13. app/Models/Article.php:1569
      • 14. app/Http/Controllers/ArticleController.php:2520
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select CONCAT_WS(' ',au.first_name, ' ', ifnull(au.initials,''), ' ', au.last_name) as authors, CONCAT(au.last_name, IFNULL(CONCAT(' ', au.initials), ''), ' ', au.first_name) AS authorsRIS, CONCAT_WS(' ',au.last_name, ' ', ifnull(au.initials,''), ' ', au.first_name) as authorsCiteAs , `au`.*, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.institution,','),''), ifnull(concat(af.department,','),''), ifnull(concat(af.address,','),''), ifnull(concat(af.city,','),''), ifnull(concat(af.country,','),''), ifnull(concat(af.postal_code,','),''), ifnull(concat(af.phone,','),''), ifnull(concat(af.fax,','),''))) SEPARATOR '|')) as `author_affiliation`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.web_view,','),''))) SEPARATOR '|')) as `web_view` from `author` as `au` left join `author_affiliation` as `af` on `au`.`author_id` = `af`.`author_id` where `au`.`article_id` = '121242' group by `au`.`author_id` order by `au`.`article_id` asc, `au`.`sequence` asc
      860μsalphaeurekaselec_live_10_06_2022Author.php#86
      Bindings
      • 0: 121242
      Backtrace
      • 13. app/Models/Author.php:86
      • 14. app/Http/Controllers/ArticleController.php:2533
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      280μsalphaeurekaselec_live_10_06_2022BundleOffer.php#113
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:113
      • 14. app/Http/Controllers/ArticleController.php:2535
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `subtitle` from `journal` where `continues_publication_journal` = 1
      650μsalphaeurekaselec_live_10_06_2022Article.php#1959
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/Article.php:1959
      • 14. app/Http/Controllers/ArticleController.php:2062
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • Select j.subtitle, v.volume_id as volume_id,v.year_id,y.year as year,v.volume_name, v.total_no_of_issues, i.issue_id as issue_id,i.title as issue, i.publication_date as issue_pub_date from journal j join volume v on j.journal_id = v.journal_id join issue i on v.volume_id = i.volume_id join article a on a.issue_id = i.issue_id join year y on v.year_id = y.id where j.journal_id = 1 and i.is_uploaded = 1 order by v.volume_name+0 desc, i.title+0 desc limit 1
      35.4msalphaeurekaselec_live_10_06_2022Issue.php#295
      Backtrace
      • 11. app/Models/Issue.php:295
      • 12. app/Http/Controllers/ArticleController.php:2068
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 1 and a.journal_id = 1 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`last_modified` desc
      16.82msalphaeurekaselec_live_10_06_2022Article.php#527
      Backtrace
      • 13. app/Models/Article.php:527
      • 14. app/Http/Controllers/ArticleController.php:2070
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 4 and a.journal_id = 1 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`last_modified` desc
      15.05msalphaeurekaselec_live_10_06_2022Article.php#527
      Backtrace
      • 13. app/Models/Article.php:527
      • 14. app/Http/Controllers/ArticleController.php:2071
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select pdf, html, epub, prc from `article_metrics` where `article_id` = 121242 limit 1
      240μsalphaeurekaselec_live_10_06_2022Article.php#743
      Bindings
      • 0: 121242
      Backtrace
      • 14. app/Models/Article.php:743
      • 15. app/Http/Controllers/ArticleController.php:2091
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from content_by_diseases where content_id = 121242 and content_type = 'article' order by status desc limit 1
      240μsalphaeurekaselec_live_10_06_2022Article.php#750
      Backtrace
      • 11. app/Models/Article.php:750
      • 12. app/Http/Controllers/ArticleController.php:2094
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `node_meta` where `nid` = 201596 limit 1
      190μsalphaeurekaselec_live_10_06_2022Meta.php#59
      Bindings
      • 0: 201596
      Backtrace
      • 14. app/Models/Meta.php:59
      • 15. app/Http/Controllers/ArticleController.php:2101
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      210μsalphaeurekaselec_live_10_06_2022BundleOffer.php#113
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:113
      • 14. app/Http/Controllers/ArticleController.php:2108
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `tbl_ht_submission` as `h` where `h`.`subtitle` = 'ACAMC' and (h.proposal_closing_date = 0 OR TO_DAYS(FROM_UNIXTIME(h.proposal_closing_date)) >= TO_DAYS(NOW())) order by `h`.`manuscript` asc
      300μsalphaeurekaselec_live_10_06_2022Article.php#2024
      Bindings
      • 0: ACAMC
      Backtrace
      • 13. app/Models/Article.php:2024
      • 14. app/Http/Controllers/ArticleController.php:2112
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '121242' and content_type = 'a' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      430μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2186
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `first_page` < '2507' and is_uploaded = 1 and issue_id = 11580 order by cast(first_page as SIGNED) desc limit 1
      610μsalphaeurekaselec_live_10_06_2022Article.php#1818
      Bindings
      • 0: 2507
      Backtrace
      • 14. app/Models/Article.php:1818
      • 15. app/Http/Controllers/ArticleController.php:2470
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `last_page` > '2516' and is_uploaded = 1 and issue_id = 11580 order by cast(first_page as SIGNED) asc limit 1
      610μsalphaeurekaselec_live_10_06_2022Article.php#1830
      Bindings
      • 0: 2516
      Backtrace
      • 14. app/Models/Article.php:1830
      • 15. app/Http/Controllers/ArticleController.php:2472
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `language_id` from `multilanguage` where `short_code` = 'en'
      210μsalphaeurekaselec_live_10_06_2022ArticleController.php#2497
      Bindings
      • 0: en
      Backtrace
      • 14. app/Http/Controllers/ArticleController.php:2497
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select `source_lang_label`, `target_lang_label` from `multilanguage_labels` where `target_lang_id` = 1
      240μsalphaeurekaselec_live_10_06_2022MultiLanguage.php#23
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/MultiLanguage.php:23
      • 14. app/Http/Controllers/ArticleController.php:2498
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `id` from `multilanguage_article` where `article_id` = 121242 limit 1
      2.54msalphaeurekaselec_live_10_06_2022ArticleController.php#2506
      Bindings
      • 0: 121242
      Backtrace
      • 16. app/Http/Controllers/ArticleController.php:2506
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 20. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 1 and `b`.`banner_from_date` <= 1736968201 and `b`.`banner_to_date` >= 1736968201 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.14msalphaeurekaselec_live_10_06_2022Banner.php#189
      Bindings
      • 0: 1
      • 1: J
      • 2: 1
      • 3: 1736968201
      • 4: 1736968201
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:189
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select count(*) as aggregate from `uc_cart_products` where cart_id='359a397737bdfb15eb8df2dfbdd306ad'
      210μsalphaeurekaselec_live_10_06_2022Cart.php#271
      Backtrace
      • 15. app/Models/Cart.php:271
      • 16. view::layouts._main_menu:13
      • 18. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 20. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    App\Models\MultiLanguage
    1MultiLanguage.php#?
        _token
        eBi1gQ5gZYU3MPgXOOogjKk75LVe7flE24sgNOst
        uc_cart_id
        359a397737bdfb15eb8df2dfbdd306ad
        _previous
        array:1 [ "url" => "https://beta.benthamscience.com/article/121242" ]
        _flash
        array:2 [ "old" => [] "new" => [] ]
        PHPDEBUGBAR_STACK_DATA
        []
        path_info
        /article/121242
        status_code
        200
        
        status_text
        OK
        format
        html
        content_type
        text/html; charset=UTF-8
        request_query
        []
        
        request_request
        []
        
        request_headers
        0 of 0
        array:16 [ "x-https" => array:1 [ 0 => "1" ] "host" => array:1 [ 0 => "beta.benthamscience.com" ] "priority" => array:1 [ 0 => "u=0, i" ] "accept-encoding" => array:1 [ 0 => "gzip, deflate, br, zstd" ] "sec-fetch-dest" => array:1 [ 0 => "document" ] "sec-fetch-user" => array:1 [ 0 => "?1" ] "sec-fetch-mode" => array:1 [ 0 => "navigate" ] "sec-fetch-site" => array:1 [ 0 => "none" ] "accept" => array:1 [ 0 => "text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7" ] "user-agent" => array:1 [ 0 => "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)" ] "upgrade-insecure-requests" => array:1 [ 0 => "1" ] "sec-ch-ua-platform" => array:1 [ 0 => ""Windows"" ] "sec-ch-ua-mobile" => array:1 [ 0 => "?0" ] "sec-ch-ua" => array:1 [ 0 => ""HeadlessChrome";v="129", "Not=A?Brand";v="8", "Chromium";v="129"" ] "cache-control" => array:1 [ 0 => "no-cache" ] "pragma" => array:1 [ 0 => "no-cache" ] ]
        request_cookies
        []
        
        response_headers
        0 of 0
        array:5 [ "content-type" => array:1 [ 0 => "text/html; charset=UTF-8" ] "cache-control" => array:1 [ 0 => "no-cache, private" ] "date" => array:1 [ 0 => "Wed, 15 Jan 2025 19:10:01 GMT" ] "set-cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6IldhbUNWRTVtZDRiWWRZMU5RaTlja2c9PSIsInZhbHVlIjoiRlpWU3FhbzlMUi9tV3dVa0tyK3BvWngyK3N5WTNkUUx2MG1hV0dIZVB6Y25TYjcvT3BrWnh3TWZpNHR6eHBiTVhtTXArN3JJRWJBa2NkemdTZWlyOUVjWTc2Umo1bDZJQ1U1NzRsMlNjTmM0Mm9mMW5IUnUzSHcvVDRxb3BpMlciLCJtYWMiOiI1YTE5OTkwOTZjNmEyZWJkMjY0NjdjZWFjODdlNzQ1MmQwZjYzMGM5MDYyMWJmZWI4MzVhY2VjNDlhNjkyM2VjIiwidGFnIjoiIn0%3D; expires=Sat, 18 Jan 2025 07:10:01 GMT; Max-Age=216000; path=/; secure; samesite=strictXSRF-TOKEN=eyJpdiI6IldhbUNWRTVtZDRiWWRZMU5RaTlja2c9PSIsInZhbHVlIjoiRlpWU3FhbzlMUi9tV3dVa0tyK3BvWngyK3N5WTNkUUx2MG1hV0dIZVB6Y25TYjcvT3BrWnh3TWZpNHR6eHBiTVhtTXArN" 1 => "eurekaselectnew_session=eyJpdiI6IjFuYzR0K0Y2S0FUTTFsREM4Z1BmWHc9PSIsInZhbHVlIjoiSHhLRERuYUhHR0ZLRWYzc0ltWEg1aExYMHdRQ2FpLzVPY1ZFZVMvVHVNVE4weGV1SkVpN25naVFPcnRhQWlaSzBJU2V4cVdtRlBYdUduVHk1Y1dwYjVGblZXRzBUMFJWVnBCelVMdUt4d2czNzFUWjc2dllvSS80UlRKa2xMdEoiLCJtYWMiOiJjMmZlNjM2Yzk0NjM3YTViODc0MGQ5MjE0NjYwNjY2MDU0MjIxZjI5MjA2OTcwZDVjMGFlYzhjMzRhZTBmMjVkIiwidGFnIjoiIn0%3D; path=/; secure; httponly; samesite=stricteurekaselectnew_session=eyJpdiI6IjFuYzR0K0Y2S0FUTTFsREM4Z1BmWHc9PSIsInZhbHVlIjoiSHhLRERuYUhHR0ZLRWYzc0ltWEg1aExYMHdRQ2FpLzVPY1ZFZVMvVHVNVE4weGV1SkVpN25naVFPcnRh" ] "Set-Cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6IldhbUNWRTVtZDRiWWRZMU5RaTlja2c9PSIsInZhbHVlIjoiRlpWU3FhbzlMUi9tV3dVa0tyK3BvWngyK3N5WTNkUUx2MG1hV0dIZVB6Y25TYjcvT3BrWnh3TWZpNHR6eHBiTVhtTXArN3JJRWJBa2NkemdTZWlyOUVjWTc2Umo1bDZJQ1U1NzRsMlNjTmM0Mm9mMW5IUnUzSHcvVDRxb3BpMlciLCJtYWMiOiI1YTE5OTkwOTZjNmEyZWJkMjY0NjdjZWFjODdlNzQ1MmQwZjYzMGM5MDYyMWJmZWI4MzVhY2VjNDlhNjkyM2VjIiwidGFnIjoiIn0%3D; expires=Sat, 18-Jan-2025 07:10:01 GMT; path=/; secureXSRF-TOKEN=eyJpdiI6IldhbUNWRTVtZDRiWWRZMU5RaTlja2c9PSIsInZhbHVlIjoiRlpWU3FhbzlMUi9tV3dVa0tyK3BvWngyK3N5WTNkUUx2MG1hV0dIZVB6Y25TYjcvT3BrWnh3TWZpNHR6eHBiTVhtTXArN" 1 => "eurekaselectnew_session=eyJpdiI6IjFuYzR0K0Y2S0FUTTFsREM4Z1BmWHc9PSIsInZhbHVlIjoiSHhLRERuYUhHR0ZLRWYzc0ltWEg1aExYMHdRQ2FpLzVPY1ZFZVMvVHVNVE4weGV1SkVpN25naVFPcnRhQWlaSzBJU2V4cVdtRlBYdUduVHk1Y1dwYjVGblZXRzBUMFJWVnBCelVMdUt4d2czNzFUWjc2dllvSS80UlRKa2xMdEoiLCJtYWMiOiJjMmZlNjM2Yzk0NjM3YTViODc0MGQ5MjE0NjYwNjY2MDU0MjIxZjI5MjA2OTcwZDVjMGFlYzhjMzRhZTBmMjVkIiwidGFnIjoiIn0%3D; path=/; secure; httponlyeurekaselectnew_session=eyJpdiI6IjFuYzR0K0Y2S0FUTTFsREM4Z1BmWHc9PSIsInZhbHVlIjoiSHhLRERuYUhHR0ZLRWYzc0ltWEg1aExYMHdRQ2FpLzVPY1ZFZVMvVHVNVE4weGV1SkVpN25naVFPcnRh" ] ]
        session_attributes
        0 of 0
        array:5 [ "_token" => "eBi1gQ5gZYU3MPgXOOogjKk75LVe7flE24sgNOst" "uc_cart_id" => "359a397737bdfb15eb8df2dfbdd306ad" "_previous" => array:1 [ "url" => "https://beta.benthamscience.com/article/121242" ] "_flash" => array:2 [ "old" => [] "new" => [] ] "PHPDEBUGBAR_STACK_DATA" => [] ]
        ClearShow all
        Date ↕MethodURLData
        #12025-01-15 19:10:01GET/article/12124248301